Sinogliatin

Drug Profile

Sinogliatin

Alternative Names: HMS-5552; RO-5305552

Latest Information Update: 19 Oct 2016

Price : $50

At a glance

  • Originator Roche
  • Developer Hua Medicine
  • Class Antihyperglycaemics; Small molecules
  • Mechanism of Action Glucokinase stimulants; Glucose modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Type 2 diabetes mellitus

Most Recent Events

  • 16 Oct 2016 Positive efficacy and safety data from a phase II trial in Type II Diabetes Mellitus released by Hua Medicine
  • 16 Oct 2016 Hua Medicine plans multiple phase III trials for Type-2 diabetes mellitus in the USA and Europe
  • 30 Sep 2016 Hua Medicine completes a phase II trial in Type 2 Diabetes Mellitus in China (NCT02561338)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top